Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine

被引:36
作者
Bashi, Tomer [1 ]
Blank, Miri [1 ]
Shor, Dana Ben-Ami [1 ]
Fridkin, Mati [2 ]
Versini, Mathilde [1 ,3 ]
Gendelman, Omer [1 ]
Volkov, Alexander [4 ]
Barshak, Iris [4 ]
Shoenfeld, Yehuda [1 ,5 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, IL-69978 Tel Aviv, Israel
[2] Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel
[3] Univ Nice Sophia Antipolis, Archet Hosp 1, Dept Internal Med, F-06189 Nice, France
[4] Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Inst Pathol, IL-69978 Tel Aviv, Israel
[5] Tel Aviv Univ, Incumbent Laura Schwarz Kipp Chair Res Autoimmune, Inst Pathol, IL-69978 Tel Aviv, Israel
关键词
Phosphorylcholine; Tuftsin; Lupus mice; Helminths; Autoimmunity; TRICHURIS-SUIS THERAPY; IMMUNE-RESPONSE; HYGIENE HYPOTHESIS; ES-62; DISEASE; INNATE; ERYTHEMATOSUS; AUTOIMMUNITY; ANTIBODIES; HELMINTHS;
D O I
10.1016/j.jaut.2015.03.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In areas where helminths infections are common, autoimmune diseases are rare. Treatment with helminths and ova from helminths, improved clinical findings of inflammatory bowel disease, multiple-sclerosis and rheumatoid-arthritis. The immunomodulatory functions of some helminths were attributed to the phosphoiylcholine (PC) moiety. We aimed to decipher the tolerogenic potential of Tuftsin-PC (TPC) compound in mice genetically prone to develop lupus. Lupus prone NZBXW/F1 mice received subcutaneously TPC (5 mu g/1 ml), 3 times a week starting at 14 weeks age. Autoantibodies were tested by ELISA, T-regulatory-cells by FACS, cytokines profile by RT-PCR and cytokines protein levels by DuoSet ELISA. Glomerulonephritis was addressed by detection of proteinuria, and immunoglobulin complex deposition in the mesangium of the kidneys of the mice by immunofluorescence. Our results show that TPC attenuated the development of glomerulonephritis in lupus prone mice, in particular, it ameliorated proteinuria (p < 0.02), and reduced immunoglobulin deposition in the kidney mesangium. TPC also enhanced the expression of TGF beta and IL-10 (p < 0.001), and inhibited the production of IFN gamma and IL-17 (p < 0.03). TPC Significantly enhanced the expansion of CD4+CD25+FOXP3+ T-regulatory cells (Tregs) phenotype in the treated mice. These data indicate that TPC hampered lupus development in genetically lupus prone mice which was exemplified by moderate glomerulonephritis, attenuation of pro-inflammatory cytokines and enhancement of anti-inflammatory cytokines expression, as well as Tregs expansion. Our results propose harnessing novel natural therapy for lupus patients. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 54 条
[1]  
Al-Riyami Lamyaa, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P45
[2]   Balance between Regulatory T and Th17 Cells in Systemic Lupus Erythematosus: The Old and the New [J].
Alunno, Alessia ;
Bartoloni, Elena ;
Bistoni, Onelia ;
Nocentini, Giuseppe ;
Ronchetti, Simona ;
Caterbi, Sara ;
Valentini, Valentina ;
Riccardi, Carlo ;
Gerli, Roberto .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
[3]   Protective immune mechanisms in helminth infection [J].
Anthony, Robert M. ;
Rutitzky, Laura I. ;
Urban, Joseph F., Jr. ;
Stadecker, Miguel J. ;
Gause, William C. .
NATURE REVIEWS IMMUNOLOGY, 2007, 7 (12) :975-987
[4]   β2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3β expression and reduces experimental-antiphospholipid-syndrome [J].
Blank, Miri ;
Baraam, Liran ;
Eisenstein, Miriam ;
Fridkin, Mati ;
Dardik, Rima ;
Heldman, Yehudit ;
Katchalski-Katzir, Ephraim ;
Shoenfeld, Yehuda .
JOURNAL OF AUTOIMMUNITY, 2011, 37 (01) :8-17
[5]   Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice [J].
Chen, M ;
Aosai, F ;
Norose, K ;
Mun, HS ;
Ishikura, H ;
Hirose, S ;
Piao, LX ;
Fang, H ;
Yano, A .
INTERNATIONAL IMMUNOLOGY, 2004, 16 (07) :937-946
[6]   Sequential therapies for proliferative lupus nephritis [J].
Contreras, G ;
Pardo, V ;
Leclercq, B ;
Lenz, O ;
Tozman, E ;
O'Nan, P ;
Roth, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) :971-980
[7]   TUFTSIN - ITS CHEMISTRY, BIOLOGY, AND CLINICAL POTENTIAL [J].
FRIDKIN, M ;
NAJJAR, VA .
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 24 (01) :1-40
[8]   Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells [J].
Goodridge, H. S. ;
McGuiness, S. ;
Houston, K. M. ;
Egan, C. A. ;
Al-Riyami, L. ;
Alcocer, M. J. C. ;
Harnett, M. M. ;
Harnett, W. .
PARASITE IMMUNOLOGY, 2007, 29 (03) :127-137
[9]  
GREENWOOD BM, 1970, CLIN EXP IMMUNOL, V7, P75
[10]   Belimumab for Systemic Lupus Erythematosus [J].
Hahn, Bevra Hannahs .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (16) :1528-1535